West Tower Group’s ARK Genomic Revolution ETF ARKG Stock Holding History

West Tower Group’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,300	Closed	-$269K	–	36
2025 Q4	$269K	Buy	+9,300	New	+$279K	0.61%	58

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

West Tower Group's ARKG Position: Q1 2026 in Review

West Tower Group sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2026, closing a stake of 9,300 shares — an estimated $269K sold.

West Tower Group first reported a position in ARKG in Q4 2025 and held it in 1 quarter. The position peaked at $269K in Q4 2025. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

West Tower Group reported no remaining ARK Genomic Revolution ETF position as of Q1 2026 after selling out during the quarter.
West Tower Group sold 9,300 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $269K.
West Tower Group first reported a position in ARK Genomic Revolution ETF in Q4 2025 and held it in 1 quarter.
West Tower Group's ARK Genomic Revolution ETF position peaked at $269K in Q4 2025.
218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on West Tower Group's 13F filing for Q1 2026, filed 29 Apr 2026.